[{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"TYK","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Betta Pharmaceuticals","amount2":0.39000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Betta Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"}]